156 results on '"Qin, Bao-Dong"'
Search Results
2. Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8+T cells
3. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M
4. Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC
5. The Association Between Tumor Burden and the Efficacy of Immunotherapy Among Patients With Non-small Cell Lung Cancer.
6. Cetuximab and vemurafenib plus liposomal irinotecan (II), leucovorin and fluorouracil for BRAF V600E -mutated advanced colorectal cancer (IMPROVEMENT2): A multicenter, open-label, randomized controlled trial.
7. The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer
8. Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy
9. Clinical, pathological and treatment factors associated with the survival of patients with primary pulmonary salivary gland-type tumors
10. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base
11. Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy
12. Primary pulmonary leiomyosarcoma: A population-based study
13. Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report
14. Pan‐cancer efficacy and safety of anlotinib plus PD ‐1 inhibitor in refractory solid tumor: A single‐arm, open‐label, phase II trial
15. Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)
16. Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy
17. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M
18. Red blood cell distribution width and neutrophil/lymphocyte ratio are positively correlated with disease activity in primary Sjögren's syndrome
19. Response to Pyrotinib in a Chinese Patient with Bone-Metastatic Scrotal Paget’s Disease Harboring Triple Uncommon HER2 Mutation: A Case Report
20. Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8+T cells
21. Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial
22. Prognostic value of red blood cell distribution width in acute pancreatitis patients admitted to intensive care units: an analysis of a publicly accessible clinical database MIMIC II
23. Effect of Smoking Status on the Efficacy of EGFR-TKI Plus Anti-Angiogenic Agent in Advanced EGFR-Mutant NSCLC
24. Risk and Incidence of Infection with Bevacizumab in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis
25. Low-Dose Anti-VEGFR2 Therapy Promotes Anti-Tumor Immunity in Lung Adenocarcinoma by Down-Regulating the Expression of Layilin on Tumor-Infiltrating CD8 +T Cells
26. Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8+T cells.
27. Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma
28. Cryptanalysis of a Type of CRT-Based RSA Algorithms
29. HER2Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma
30. Primary squamous cell carcinoma of pancreas: a population-based study
31. Prognostic Value of Diverse TP53 Mutations in Metastatic Cancers: An Analysis of the Cbioportal Database
32. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer
33. Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib
34. Metastatic Low-Grade Sarcoma with CARS-ALK Fusion Dramatically Responded to Multiple ALK Tyrosine Kinase Inhibitors: A Case Report with Comprehensive Genomic Analysis
35. Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types
36. Identification of clinical features to predict the consistency of mutational profiles obtained from plasma and tissue of advanced non-small cell lung cancer (NSCLC) patients.
37. MTSS1 inhibits metastatic potential and induces G2/M phase cell cycle arrest in gastric cancer
38. Response to Pyrotinib in a Chinese Patient with Bone-Metastatic Scrotal Paget’s Disease Harboring Triple Uncommon HER2 Mutation: A Case Report
39. HER2 Splice Site Mutation c.1899‐1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2‐Positive Gastric Adenocarcinoma.
40. A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy
41. The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review
42. Palbociclib for the Treatment of Metastatic Nasopharyngeal Carcinoma With CDK4 Amplification: A Case Report
43. The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base
44. Basket Trials for Intractable Cancer
45. MTSS1 inhibits metastatic potential and induces G2/M phase cell cycle arrest in gastric cancer
46. Metastatic Low‐Grade Sarcoma with CARS‐ALK Fusion Dramatically Responded to Multiple ALK Tyrosine Kinase Inhibitors: A Case Report with Comprehensive Genomic Analysis.
47. Adenosquamous carcinoma of the bile duct: a population-based study
48. Red blood cell distribution width and mean platelet volume are potential prognostic indices for patients with primary biliary cirrhosis
49. Elevated red blood cell distribution width is associated with liver function tests in patients with primary hepatocellular carcinoma
50. Gene expression profile of THP-1 cells treated with heat-killed Candida albicans
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.